Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA.
J Dermatol Sci. 2010 Oct;60(1):29-39. doi: 10.1016/j.jdermsci.2010.07.015. Epub 2010 Aug 10.
The serine/threonine kinase protein kinase D (PKD) has been proposed to be a pro-proliferative, anti-differentiative signal in epidermal keratinocytes. Indeed, the phorbol ester tumor promoter, 12-O-tetradecanoylphorbol 13-acetate (TPA) induces biphasic PKD activation, which mirrors the biphasic response of initial differentiation followed by proliferation and tumor promotion seen in TPA-treated keratinocytes in vitro and epidermis in vivo.
Our objective was to test the idea that PKD's pro-proliferative and/or anti-differentiative effects in keratinocytes contribute to TPA-induced tumorigenesis.
Using western analysis and assays of keratinocyte proliferation and differentiation, we investigated the effect of inhibitors of PKD on keratinocyte function.
We found that overexpression of a constitutively active PKD mutant increased, and of a dominant-negative PKD mutant decreased, keratinocyte proliferation. A recently described selective PKD inhibitor showed low potency to inhibit keratinocyte proliferation or PKD activation. Therefore, we tested the ability of known only relatively selective PKD inhibitors on keratinocyte function and protein kinase activation. H89 {N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinoline-sulfonamide}, a reported inhibitor of PKD and cAMP-dependent protein kinase, enhanced the effect of a differentiating agent on a marker of keratinocyte differentiation. Another reported non-selective PKD inhibitor, resveratrol stimulated differentiation and inhibited proliferation. The protein kinase C/PKD inhibitor Gö6976 blocked the increase in proliferation (as measured by DNA specific activity) induced by chronic TPA without affecting the initial TPA-elicited differentiation.
Our results support the idea that relatively selective PKD inhibitors, such as Gö6976, H89 and resveratrol, might be useful for preventing/treating epidermal tumorigenesis without affecting keratinocyte differentiation.
丝氨酸/苏氨酸蛋白激酶蛋白激酶 D(PKD)已被提出为表皮角质形成细胞中的促有丝分裂、抗分化信号。事实上,佛波酯肿瘤促进剂 12-O-十四烷酰佛波醇 13-乙酸酯(TPA)诱导 PKD 的双相激活,这反映了 TPA 处理的角质形成细胞体外和体内表皮中初始分化后增殖和肿瘤促进的双相反应。
我们的目的是检验 PKD 在角质形成细胞中的促有丝分裂和/或抗分化作用是否有助于 TPA 诱导的肿瘤发生。
使用 Western 分析和角质形成细胞增殖和分化测定,我们研究了 PKD 抑制剂对角质形成细胞功能的影响。
我们发现,组成型激活 PKD 突变体的过表达增加了,显性负 PKD 突变体的过表达减少了角质形成细胞的增殖。最近描述的选择性 PKD 抑制剂对角质形成细胞增殖或 PKD 激活的抑制作用较低。因此,我们测试了已知仅具有相对选择性 PKD 抑制剂对角质形成细胞功能和蛋白激酶激活的能力。H89[N-[2-(对溴肉桂酰基)氨基]乙基]-5-异喹啉磺酰胺],一种报道的 PKD 和 cAMP 依赖性蛋白激酶抑制剂,增强了分化剂对角质形成细胞分化标志物的作用。另一种报道的非选择性 PKD 抑制剂白藜芦醇刺激分化并抑制增殖。蛋白激酶 C/ PKD 抑制剂 Gö6976 阻断了慢性 TPA 诱导的增殖增加(如通过 DNA 特异性活性测量),而不影响初始 TPA 引发的分化。
我们的结果支持这样一种观点,即相对选择性 PKD 抑制剂,如 Gö6976、H89 和白藜芦醇,可能有助于预防/治疗表皮肿瘤发生,而不影响角质形成细胞分化。